FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely ophthalmology. The method involves a transepithelial corneal collagen crosslinking. That is preceded with a single bath electrophoresis with 1% riboflavin mononucleotide. That is ensured by an initial current of 0.2 mA to be increased gradually to 1 mA, at a pitch of 0.2 mA for 2 minutes. That is followed by an ultraviolet corneal exposure. The exposure is conducted at wave length 370 nm, power 3 mWt/cm2 and combined with instillation of a riboflavin solution. The solution contains 0.1% riboflavin mononucleotide and 20% dextran.
EFFECT: method provides more effective riboflavin delivery to the corneal stroma for one procedure providing the intraocular protection against ultraviolet light.
2 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
| METHOD OF TREATING KERATOCONUS STAGE I-II | 2022 |
|
RU2819801C2 |
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
| OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
| METHOD OF TREATING KERATOCONUS, INCLUDING IN PATIENTS WITH CORNEAL THICKNESS OF LESS THAN 450 MICRONS, USING ULTRAVIOLET CROSS-LINKING OF CORNEAL COLLAGEN IN COMBINATION WITH PERSONALIZED TRANSEPITHELIAL PHOTOREFRACTIVE KERATECTOMY | 2023 |
|
RU2814093C1 |
| METHOD FOR CONDUCTING ULTRAVIOLET CORNEAL CROSS-LINKING USING BIOLENS WITH THIN CORNEA | 2020 |
|
RU2739995C1 |
| METHOD FOR CORNEAL COLLAGEN CROSSLINKING | 2021 |
|
RU2768181C1 |
| METHOD OF PROTECTION OF CORNEA AND LIMBAL ZONE OF EYE FROM INFLUENCE OF ULTRAVIOLET IRRADIATION IN CROSSLINKING | 2012 |
|
RU2496457C1 |
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
